Anti-Cancer Drugs Effective in Retinoblastoma: Based on a Protein-Protein Interaction Network
Journal of Ophthalmic and Optometric Sciences,
Vol. 4 No. 2 (2020),
10 April 2020
,
Page 27-40
https://doi.org/10.22037/joos.v3i4.36778
Abstract
Background: This paper investigates the effects of potential drugs on differentially expressed genes (DEGs) associated with substantial alterations in retinoblastoma malignancy.
Material and Methods: The GSE125903 dataset consisting of ten samples was used in this study (seven cancer patients and three control samples). The genes were ordered according to their adjusted p value, and 2000 top differential expressed genes with adj p values less than 0.01 were chosen as statistically significant. The STRING database version 11.0 was used to display the interaction among genes. The Cytoscape3.8.2 and the Clusterviz plugin software were used to construct the modules for the PPI network, and five clusters of genes were formed. The DGIdb v4.2.0 database was used to study drug-gene interactions and identify potentially beneficial medicines for retinoblastoma malignancy. The DAVID v.6.8 database was used to study gene ontology (GO) and important biological pathways.
Results: CISPLATIN, TAMOXIFEN, and CYCLOPHOSPHAMIDE are the medicines that have been shown to be successful in treating retinoblastoma in our study. Additionally, we conducted a research on three other drugs: GEMCITABINE, OLAPARIB, and MITOXANTRONE. Although it is used to treat other diseases, it seems to have no apparent effects on retinoblastoma cancer treatment.
Conclusion: CISPLATIN, a drug that causes apoptosis in tumors, has been proven to be the most effective therapy for retinoblastoma and should be included in treatment regimens for this illness. Of course, we obtained this information based on bioinformatics techniques, and more clinical trials are needed for more reliable results.
Keywords: Protein-Protein Interaction Network; Retinoblastoma; Anti-Cancer.
- protein-protein interaction network
- retinoblastoma
- Anti-cancer
How to Cite
References
Dimaras H, Kimani K, Dimba EA, Gronsdahl P, White A, Chan HS, et al. Retinoblastoma. The Lancet. 2012;379(9824):1436-46.
Rao R, Honavar SG. Retinoblastoma. The Indian Journal of Pediatrics. 2017;84(12):937-44. doi: 10.1007/s12098-017-2395-0.
Seigel GM, Campbell LM, Narayan M, Gonzalez-Fernandez F. Cancer stem cell characteristics in retinoblastoma. Mol Vis. 2005;11(12):729-37.
Dimaras H, Corson TW, Cobrinik D, White A, Zhao J, Munier FL, et al. Retinoblastoma. Nature Reviews Disease Primers. 2015;1(1):15021. doi: 10.1038/nrdp.2015.21.
Mousavian Z, Díaz J, Masoudi-Nejad A. Information theory in systems biology. Part II: protein-protein interaction and signaling networks. Seminars in cell & developmental biology. 2016;51:14-23. doi: 10.1016/J.SEMCDB.2015.12.006.
Mousavian Z, Kavousi K, Masoudi-Nejad A. Information theory in systems biology. Part I: Gene regulatory and metabolic networks. Seminars in Cell and Developmental Biology. 2016;51:3-13. doi: 10.1016/j.semcdb.2015.12.007.
Torkamanian-Afshar M, Lanjanian H, Nematzadeh S, Tabarzad M, Najafi A, Kiani F, et al. RPINBASE: An online toolbox to extract features for predicting RNA-protein interactions. Genomics. 2020;112(3). doi: 10.1016/j.ygeno.2020.02.013.
Masoudi-Nejad A, Goto S, Endo TR, Kanehisa M. KEGG bioinformatics resource for plant genomics research. Methods in molecular biology (Clifton, NJ). 2007;406:437-58. doi: 10.1007/978-1-59745-535-0_21.
Ghasemi M, Seidkhani H, Tamimi F, Rahgozar M, Masoudi-Nejad A. Centrality Measures in Biological Networks. Current Bioinformatics. 2014;9(4):426-41. doi: 10.2174/15748936113086660013.
Kouhsar M, Azimzadeh Jamalkandi S, Moeini A, Masoudi-Nejad A. Detection of novel biomarkers for early detection of Non-Muscle-Invasive Bladder Cancer using Competing Endogenous RNA network analysis. Scientific Reports 2019 9:1. 2019;9(1):1-15. doi: 10.1038/s41598-019-44944-3.
H L, S N, S H, M T-A, F K, M M-J, et al. High-throughput analysis of the interactions between viral proteins and host cell RNAs. Computers in biology and medicine. 2021;135:104611-. doi: 10.1016/J.COMPBIOMED.2021.104611.
Motieghader H, Kouhsar M Fau - Najafi A, Najafi A Fau - Sadeghi B, Sadeghi B Fau - Masoudi-Nejad A, Masoudi-Nejad A. mRNA-miRNA bipartite network reconstruction to predict prognostic module biomarkers in colorectal cancer stage differentiation. (1742-2051 (Electronic)).
MotieGhader H, Masoudi-Sobhanzadeh Y, Ashtiani SH, Masoudi-Nejad A. mRNA and microRNA selection for breast cancer molecular subtype stratification using meta-heuristic based algorithms. (1089-8646 (Electronic)).
Mastrangelo D, De Francesco S, Di Leonardo A, Lentini L, Hadjistilianou T. Retinoblastoma epidemiology: Does the evidence matter? European Journal of Cancer. 2007;43(10):1596-603. doi: https://doi.org/10.1016/j.ejca.2007.04.019.
Lohmann DR, Gallie BL. Retinoblastoma: Revisiting the model prototype of inherited cancer. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2004;129C(1):23-8. doi: https://doi.org/10.1002/ajmg.c.30024.
Villegas VM, Hess DJ, Wildner A, Gold AS, Murray TG. Retinoblastoma. Current Opinion in Ophthalmology. 2013;24(6):581-8. doi: 10.1097/icu.0000000000000002. PubMed PMID: 00055735-201311000-00010.
Ortiz MV, Dunkel IJ. Retinoblastoma. Journal of Child Neurology. 2016;31(2):227-36. doi: 10.1177/0883073815587943. PubMed PMID: 26023180.
Parulekar MV. Retinoblastoma — Current treatment and future direction. Early Human Development. 2010;86(10):619-25. doi: https://doi.org/10.1016/j.earlhumdev.2010.08.022.
DiCiommo D, Gallie BL, Bremner R. Retinoblastoma: the disease, gene and protein provide critical leads to understand cancer. Seminars in Cancer Biology. 2000;10(4):255-69. doi: https://doi.org/10.1006/scbi.2000.0326.
Rodriguez-Galindo C, Orbach DB, VanderVeen D. Retinoblastoma. Pediatric Clinics of North America. 2015;62(1):201-23. doi: https://doi.org/10.1016/j.pcl.2014.09.014.
Freshour SL, Kiwala S, Cotto KC, Coffman AC, McMichael JF, Song JJ, et al. Integration of the Drug-Gene Interaction Database (DGIdb 4.0) with open crowdsource efforts. Nucleic Acids Res. 2021;49(D1):D1144-D51. doi: 10.1093/nar/gkaa1084. PubMed PMID: 33237278.
Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature Protocols. 2009;4(1):44-57. doi: 10.1038/nprot.2008.211.
Di Felice V, Lauricella M, Giuliano M, Emanuele S, Vento R, Tesoriere G. The apoptotic effects of cisplatin and carboplatin in retinoblastoma Y79 cells. Int J Oncol. 1998;13(2):225-57. doi: 10.3892/ijo.13.2.225.
Song HB, Jun H-O, Kim JH, Yu YS, Kim K-W, Min BH, et al. Anti-apoptotic effect of clusterin on cisplatin-induced cell death of retinoblastoma cells. Oncol Rep. 2013;30(6):2713-8. doi: 10.3892/or.2013.2764.
Kulkarni AD, van Ginkel PR, Darjatmoko SR, Lindstrom MJ, Albert DM. Use of combination therapy with cisplatin and calcitriol in the treatment of Y-79 human retinoblastoma xenograft model. British Journal of Ophthalmology. 2009;93(8):1105. doi: 10.1136/bjo.2008.152843.
Taçyildiz N, Yavuz G, Ünal E, Gündüz K, Günalp İ, Ekinci C. Encouraging Result of Tamoxifen in a Retinoblastoma Patient with Central Nervous System Metastasis. Pediatric Hematology and Oncology. 2003;20(6):473-6. doi: 10.1080/08880010390220072.
Malik RK, Friedman HS, Djang WT, Falletta JM, Buckley E, Kurtzberg J, et al. Treatment of Trilateral Retinoblastoma With Vincristine and Cyclophosphamide. American Journal of Ophthalmology. 1986;102(5):650-6. doi: https://doi.org/10.1016/0002-9394(86)90540-4.
White L, Reed C, Tobias V. Comparison of Cyclophosphamide and Diaziquone in a Retinoblastoma Xenograft Model. Ophthalmic Paediatrics and Genetics. 1989;10(2):99-105. doi: 10.3109/13816818909088349.
Varan A, Kiratli H, Aydın B, Tarlan B, Poyraz CB, Akyüz C, et al. The Treatment of Retinoblastoma with Four-Drug Regimen Including Cisplatin, Etoposide, Vincristine, and Cyclophosphamide. Pediatric Hematology and Oncology. 2012;29(6):529-37. doi: 10.3109/08880018.2012.700387.
Kawamura J, Sakurai M, Tsukamoto K, Tochigi H. Leiomyosarcoma of the Bladder Eighteen Years after Cyclophosphamide Therapy for Retinoblastoma. Urologia Internationalis. 1993;51(1):49-53. doi: 10.1159/000282511.
Parekh DJ, Jung C, O’Conner J, Dutta S, Smith ER. Leiomyosarcoma in urinary bladder after cyclophosphamide therapy for retinoblastoma and review of bladder sarcomas. Urology. 2002;60(1):164. doi: https://doi.org/10.1016/S0090-4295(02)01701-6.
Luigi Motta ABPVFADAQPLC. Leiomyosarcoma of the Bladder Fourteen Years After Cyclophosphamide Therapy for Retinoblastoma. Scandinavian Journal of Urology and Nephrology. 2001;35(3):248-9. doi: 10.1080/003655901750292060.
Noble S, Goa KL. Gemcitabine. Drugs. 1997;54(3):447-72. doi: 10.2165/00003495-199754030-00009.
Wang Z, Gao J, Zhou J, Liu H, Xu C. Olaparib induced senescence under P16 or P53 dependent manner in ovarian cancer. jgo. 2018;30(2):0-. doi: 10.3802/jgo.2019.30.e26.
Fox EJ. Mechanism of action of mitoxantrone. Neurology. 2004;63(12 suppl 6):S15. doi: 10.1212/WNL.63.12_suppl_6.S15
- Abstract Viewed: 119 times
- pdf Downloaded: 54 times
